Navigation Links
Cardinal Health Reports Fiscal 2009 Results, Provides Fiscal 2010 Outlook
Date:8/18/2009

DUBLIN, Ohio, Aug. 18 /PRNewswire-FirstCall/ -- Cardinal Health today reported fiscal 2009 diluted earnings per share (EPS) from continuing operations of $3.16, or $3.48 on a non-GAAP basis(1), which was in line with the company's expectations and includes a $0.03 dilutive impact from the classification of the company's UK-based Martindale injectable manufacturing business as discontinued operations.

The company reported fourth-quarter diluted EPS from continuing operations of $0.74, or $0.86 on a non-GAAP basis, which includes a $0.01 dilutive impact from the Martindale classification as discontinued operations. The quarter was highlighted by the Healthcare Supply Chain Services (HSCS) segment, which reported an 8 percent increase in segment profit, driven by strong growth in the Pharmaceutical Supply Chain and Nuclear Pharmacy Services businesses, and a return to growth in its surgical and procedural kitting operations. The growth in the final quarter contributed to a slight increase of 0.4 percent in HSCS segment profit for the full fiscal year.

Fourth-quarter and full-year segment profit for the Clinical and Medical Products segment declined on a year-over-year basis within company expectations, due to the deferral in hospital capital spending and the impact from a shipping hold on its Alaris((R)) System infusion product during the second half of fiscal 2009. Sequentially from the third quarter, revenue and segment profit increased. In addition, the Alaris((R)) System shipping hold was lifted in July. The spinoff of CareFusion Corp., the company that will become public from the spinoff of Cardinal Health's Clinical and Medical Products businesses, remains on track to be completed after the close of business on Aug. 31.

"Fiscal 2009 saw accelerated investments to improve our ability to serve customers, as well as disciplined cost-containment measures, all of which will continue through an important transition year in fiscal 2010," said R. Kerry Clark, chairman and chief executive officer of Cardinal Health. "With the improvement in the core businesses within the Healthcare Supply Chain Services segment and the resumption of customer installations for the Alaris((R)) System, both Cardinal Health and CareFusion have solid foundations and initiatives in place to position themselves for long-term success."

CONSOLIDATED Q4 AND FY09 RESULTS

The company reported fourth-quarter revenue growth of 10 percent to $25.2 billion and a 15 percent decline in earnings from continuing operations to $268 million, driven by previously disclosed factors impacting the Clinical and Medical Products business with a partial offset from solid profit growth from the Healthcare Supply Chain Services segment. Special items and impairments and other costs associated with the planned spinoff decreased after-tax earnings by $44 million or $0.12 per share. Excluding these items, fourth-quarter non-GAAP earnings from continuing operations(2) declined 9 percent to $311 million.

For full fiscal 2009, consolidated revenue grew 9 percent to $99.5 billion and earnings from continuing operations declined 12 percent to $1.1 billion. The net after-tax dilutive impact from special items and impairments and the impact of other costs associated with the planned spinoff totaled $114 million or $0.32 per share. Excluding these items, non-GAAP earnings from continuing operations declined 8 percent to $1.3 billion. In addition, the company finished the year with strong consolidated operating cash flow of approximately $1.6 billion, through disciplined management of working capital.

Q4 and FY09 SUMMARY

                        Q4 FY09       Q4 FY08     Y/Y         FY09      Y/Y

    Revenue         $25.2 billion $22.9 billion    10%  $99.5 billion     9%

    Operating
     Earnings        $436 million  $527 million   (17%)  $1.9 billion   (10%)
    Non-GAAP
     Operating
     Earnings(3)     $509 million  $560 million    (9%)  $2.1 billion    (4%)

    Earnings from
     Continuing
     Operations      $268 million  $316 million   (15%)  $1.1 billion   (12%)
    Non-GAAP
     Earnings from
     Continuing
     Operations      $311 million  $342 million    (9%)  $1.3 billion    (8%)

    Diluted EPS
     from
     Continuing
     Operations             $0.74         $0.88   (16%)         $3.16   (11%)
    Non-GAAP
     Diluted EPS
     from Continuing
     Operations             $0.86         $0.96   (10%)         $3.48    (7%)

FISCAL 2009 SEGMENT RESULTS AND FISCAL 2010 OUTLOOK

Healthcare Supply Chain Services

The Healthcare Supply Chain Services segment increased fourth-quarter revenue 11 percent to $24.3 billion, driven by strong growth in the pharmaceutical supply chain business across all customer categories. Sales to bulk pharmaceutical customers(4) increased 16 percent to $11 billion and sales to non-bulk pharmaceutical customers(5) increased 9 percent to $11.1 billion. Segment profit for the quarter increased 8 percent to $341 million, driven by the profit contribution from revenue gains, growth in generics, strong performance under the company's fee-for-service arrangements with branded manufacturers, strength in nuclear pharmacy and disciplined expense management.

For the full year, segment revenue increased 10 percent to $95.7 billion, driven by solid sales across the segment. Full-year revenue from bulk pharmaceutical customers increased 17 percent to $43.7 billion and annual sales to non-bulk pharmaceutical customers increased 4 percent to $43.6 billion. Annual segment profit was slightly positive from the previous year at $1.3 billion with profit contribution from revenue gains, solid generics performance and medical supply chain growth being offset by pharmaceutical contract repricings, the impact from anti-diversion activities and bad-debt expense.

The company is in the midst of driving several important initiatives designed to optimize customer mix and improve margins. These include actions to enhance the overall experience across all customer categories, improve its generic pharmaceutical and medical product sourcing programs and enhance internal processes related to pricing. This is complemented by lean operating model initiatives, including a disciplined focus on inventory levels across all lines of business. Importantly, the medical and surgical supply chain businesses have initiated a transformation program, which is designed to implement new systems and processes to improve customer ordering and service.

"The Healthcare Supply Chain Services segment had a strong finish to a solid year," said George Barrett, incoming chairman and chief executive officer of Cardinal Health. "While we are pleased with the improvement in the supply chain segment, our work continues as we take the necessary strategic actions to drive long-term growth."

    Healthcare Supply
     Chain Services     Q4 FY09       Q4 FY08     Y/Y         FY09      Y/Y

    Revenue         $24.3 billion $21.8 billion    11%  $95.7 billion    10%
    Segment Profit   $341 million  $316 million     8%   $1.3 billion     0%

Fiscal 2010 Outlook for 'New' Cardinal Health

Excluding the businesses that will be spun off as CareFusion, Cardinal Health's adjusted fiscal 2009 revenue was $96 billion and adjusted diluted EPS from continuing operations for the full year was $2.12 or $2.26 on a non-GAAP basis(6).

"As we look forward to fiscal 2010 for 'new' Cardinal Health, we expect low single-digit revenue growth and non-GAAP diluted earnings per share from continuing operations in the range of $1.90 to $2.00, which is a slight increase from the implied range of $1.87 to $1.91 provided at our Investor Day on June 2," Barrett said. "The progress we made in fiscal 2009 reinforces our belief that the company's core businesses are strong and the investments we are making in fiscal 2010 will create a more positive and sustainable longer-term growth trajectory."

The company expects its Medical segment to contribute strong segment profit growth in fiscal 2010, which will be offset by an expected decline in Pharmaceutical segment profit, resulting from business investments, unfavorable year-over-year comparison from generic launches and customer contract repricings.

Additional Fourth-Quarter and Recent Highlights from Cardinal Health:

  • Renewed a distribution agreement with CVS Caremark to supply pharmaceuticals to its national network of retail pharmacies through mid-2013.
  • Increased the regular quarterly dividend by 25 percent to $0.175 per share, with the impact significantly increasing its expected payout ratio post-spin.
  • Record-breaking attendance at the company's Retail Business Conference, which included launches of new tools to help independent pharmacies deliver cost-effective, personalized care to more patients.
  • Announced three new members of the board of directors: George S. Barrett as chairman and chief executive officer of Cardinal Health, effective Sept. 1; Bruce L. Downey, former chairman and chief executive officer of Barr Pharmaceuticals, effective Sept. 1; and Glenn A. Britt, chairman, president and chief executive officer of Time Warner Cable, effective Oct. 1.
  • Hired Patricia Morrison as Chief Information Officer to enhance the company's enterprise-wide information technology infrastructure to support Cardinal Health's strategic business needs.

Clinical and Medical Products

Fourth-quarter revenue for the Clinical and Medical Products segment declined 12 percent to $1.1 billion, due to the continued deferral in hospital capital spending, the Alaris((R)) System shipping hold and the negative impact of foreign exchange rates. Segment profit declined 32 percent in the fourth quarter to $157 million, driven by the decline in revenue and the negative impact of foreign exchange rates. The quarterly profit decline was partially offset by aggressive spending reductions and sales of ChloraPrep((R)) from the Enturia acquisition.

Clinical and Medical Products revenue saw a slight decrease of 0.4 percent for the full year to $4.6 billion, with increases in the first half of the year being offset by the revenue decline in the second half. Segment profit was also affected by the second-half factors that impacted segment revenue and finished the year down 9 percent to $670 million. The Enturia acquisition continued to exceed expectations for the quarter and full year.

"There is no doubt that the second half of fiscal 2009 was a challenging economic environment, but we assessed and addressed the market conditions correctly," said David Schlotterbeck, chief executive officer of CareFusion. "In the fourth quarter, we saw a sequential improvement in customer orders from the third quarter and continued strong performance from the infection prevention businesses with top- and bottom-line growth. In addition, resuming customer installations of our Alaris((R)) System infusion line in July, following 510(k) clearance from the Food and Drug Administration, was an important milestone under our enhanced quality system."

    Clinical and
     Medical Products   Q4 FY09       Q4 FY08     Y/Y         FY09      Y/Y

    Revenue          $1.1 billion  $1.3 billion  (12%)   $4.6 billion     0%
    Segment Profit   $157 million  $229 million  (32%)   $670 million    (9%)

Fiscal 2010 Outlook for CareFusion

For the fiscal year ending June 30, 2010, CareFusion expects mid single-digit revenue growth compared to fiscal 2009 pro forma revenue of $3.7 billion. Adjusted diluted earnings per share(7) for fiscal 2010 are expected to be between $1.10 and $1.20, compared to fiscal 2009 pro forma adjusted diluted earnings per share of $1.54, or $1.32 on an unadjusted basis. The pro forma financials reflect CareFusion results as if the separation and related transactions had already occurred.(8)

The expected year-over-year decline in adjusted diluted earnings per share is primarily driven by an incremental $100 million to $110 million in spending CareFusion will incur due to several factors including higher compensation expense, R&D spending and costs to stand up infrastructure as a new public company. In addition the company expects a significant increase in the tax rate from fiscal 2009 to 2010, due primarily to a one-time tax benefit received in 2009.

The guidance for fiscal 2010 is based on an assumed diluted weighted average outstanding share count of 228 million and reflects a previously announced distribution ratio of 0.5 shares of CareFusion common stock for each common share of Cardinal Health held as of 5 p.m. EDT on Aug. 25.

Additional Fourth-Quarter and Recent Highlights for CareFusion:

  • Form 10 registration statement declared effective by the Securities and Exchange Commission and a private letter ruling received from the Internal Revenue Service. The spinoff is on track to be completed after the close of business on Aug. 31.
  • Launched the CareFusion brand, establishing the company as an industry leader in helping hospitals measurably improve patient care and safety.
  • Announced the nine members that will comprise the CareFusion board of directors.
  • Awarded a contract with the Centers for Disease Control to supply more than 4,500 ventilators to the National Stockpile Program.
  • Signed a five-year, exclusive agreement for Pyxis(R) brand medication dispensing equipment with HCA.
  • Pyxis(R) products named #1 in customer service from MD Buyline's April through June quarterly report, reflecting a multi-year commitment to investing in improved customer service.
  • MedMined(TM) services received #1 ranking for infection surveillance technology providers by KLAS.

CONFERENCE CALL

Cardinal Health and CareFusion will host a conference call today at 8:30 a.m. EDT to discuss the fiscal 2009 results and outlook for fiscal 2010. The conference call will be divided into two separate sessions. During the first session, Cardinal Health Chief Financial Officer Jeff Henderson will briefly review consolidated Cardinal Health financial results for the fourth quarter and fiscal 2009, including the Clinical and Medical Products businesses that are part of the planned spinoff of CareFusion. Following the consolidated discussion, Barrett will discuss a business update on 'new' Cardinal Health, and Henderson will provide adjusted financials reflecting the removal of the CareFusion businesses, followed by a discussion of fiscal 2010 expectations and assumptions. These prepared comments will be followed by a question and answer session focused on 'new' Cardinal Health and consolidated Cardinal Health results. At approximately 9:15 a.m. EDT, the call will transition to Schlotterbeck for a business update on CareFusion. Ed Borkowski, chief financial officer for CareFusion, will follow with a discussion of historical pro forma financials and expectations for fiscal 2010. CareFusion management then will address questions specific to CareFusion.

To access the call and corresponding slide presentation, visit the investor page at cardinalhealth.com or dial 617-213-4858, passcode 66270788. Participants are advised to pre-register at the investor page at cardinalhealth.com or to dial into the call at least 10 minutes prior to the start time. Pre-registrants are issued a pin number that provides faster access to the live call. Presentation slides, an audio replay and a transcript will be archived on the Web site after the conclusion of the meeting. The audio replay will also be available until 5 p.m. EDT on Aug. 25 by dialing 617-801-6888, passcode 65367949.

UPCOMING CARDINAL HEALTH EVENTS

Cardinal Health will be participating in the following health care investor conferences:

  • 2009 Thomas Weisel Partners Healthcare Conference in Boston on Sept. 10.
  • Morgan Stanley Global Healthcare Unplugged Conference in New York on Sept. 15.
  • 2009 INVESTOhio Equity Conference in Columbus, Ohio on Sept. 15.
  • UBS Global Life Sciences Conference in New York on Sept. 23.

At these events, company executives will discuss Cardinal Health's diverse products and services, company performance and strategies for continued growth. To access more details and live webcasts of these events, including remarks or a transcript, go to the Investors page at cardinalhealth.com.

About 'New' Cardinal Health

Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE: CAH) is a Fortune 18 health care services company that improves the cost-effectiveness of health care. As the business behind health care, Cardinal Health helps pharmacies, hospitals and ambulatory care sites focus on patient care while reducing costs, improving efficiency and quality, and increasing profitability. As one of the largest health care companies in the world, Cardinal Health is an essential link in the health care supply chain, providing pharmaceuticals and medical products to more than 40,000 locations each day. The company is also a leading manufacturer of medical and surgical products, including gloves, surgical apparel and fluid management products. In addition, the company supports the growing diagnostic industry by supplying medical products to clinical laboratories and operating the nation's largest network of radiopharmacies that dispense products to aid in the early diagnosis and treatment of disease. Cardinal Health employs more than 30,000 people worldwide. More information about the company may be found at cardinalhealth.com.

About CareFusion Corp.

CareFusion Corp., a wholly owned subsidiary of Cardinal Health, is expected to become a public company with the planned spinoff of the clinical and medical products businesses of Cardinal Health. The global company serves the health care industry with products and services that help hospitals measurably improve the safety and quality of health care. CareFusion develops market-leading technologies including Alaris((R)) IV pumps, Pyxis((R)) automated dispensing and patient identification systems, AVEA and Pulmonetic Systems(TM) ventilation and respiratory products, ChloraPrep((R)) for infection prevention and MedMined(TM) services for infection surveillance, neurological monitoring and diagnostic products, V. Mueller((R)) surgical instruments and an extensive line of products that support interventional medicine.

CareFusion employs more than 15,000 people across its global operations. The company has been authorized to have its shares of common stock listed on the New York Stock Exchange under the ticker symbol "CFN." More information may be found at carefusion.com.

About the planned CareFusion spinoff

Cardinal Health's board has approved the spinoff of CareFusion Corp. through a pro rata distribution of at least 80.1 percent of the shares of CareFusion common stock to Cardinal Health shareholders, with Cardinal Health retaining the remaining shares. The distribution of shares of CareFusion common stock will be made after the close of trading on Aug. 31 to Cardinal Health's shareholders of record as of 5 p.m. EDT on Aug. 25, the record date for the spinoff. Cardinal Health will distribute 0.5 share of CareFusion common stock for each common share of Cardinal Health outstanding as of the record date. Shareholders will receive cash in lieu of fractional shares of CareFusion common stock. No action is required by Cardinal Health shareholders as of the record date to receive their shares of the common stock of CareFusion Corp. in the spinoff.

(1) Non-GAAP diluted EPS from continuing operations: Non-GAAP earnings from continuing operations divided by diluted weighted average shares outstanding.

(2) Non-GAAP earnings from continuing operations: Earnings from continuing operations excluding (1) special items, (2) impairments, (gain)/loss on sale of assets and other, net and, except for adjusted results, (3) spinoff costs not included in special items or impairments, (gain)/loss on sale of assets and other, net, each net of tax.

(3) Non-GAAP operating earnings: Operating earnings excluding (1) special items, (2) impairments, (gain)/loss on sale of assets and other, net and (3) spinoff costs not included in special items or impairments, (gain)/loss on sale of assets and other, net.

(4) Bulk pharmaceutical customers consist of Healthcare Supply Chain Services customers to which the segment distributes pharmaceutical, radiopharmaceutical and over-the-counter health care products to the customers' centralized warehouse operations and mail order businesses.

(5) Non-bulk pharmaceutical customers consist of all Healthcare Supply Chain Services customers to which the segment distributes pharmaceutical, radiopharmaceutical and over-the-counter health care products other than bulk pharmaceutical customers.

(6) Cardinal Health unaudited adjusted financial results have been derived from Cardinal Health's historical consolidated financial statements and have been adjusted to present the estimated impact of removal of the CareFusion businesses from the historical financial statements of Cardinal Health. These financial results do not necessarily reflect the financial results that will be presented within Cardinal Health's consolidated financial statements subsequent to the completion of the spinoff of CareFusion. In addition, they do not reflect what the financial results would have been if Cardinal Health had actually operated without the CareFusion businesses during the periods shown nor are they necessarily indicative of Cardinal Health's future results. The assumptions and estimates used and adjustments derived from such assumptions are based on currently available information, and Cardinal Health management believes such assumptions and estimates are reasonable under the circumstances. For more information, see the Cardinal Health unaudited adjusted consolidated financial statements included as Exhibit 99.4 to Cardinal Health's Form 8-K filed on Aug. 18, 2009.

(7) CareFusion adjusted diluted earnings per share: CareFusion earnings from continuing operations adjusted to exclude (1) restructuring and acquisition integration charges (including one-time spinoff related costs) and (2) acquired in-process research and development, divided by the anticipated number of diluted weighted average shares of CareFusion common stock outstanding at spinoff. This is a non-GAAP financial measure.

(8) CareFusion unaudited pro forma financial results have been derived from the historical consolidated financial statements and accounting records of Cardinal Health, Inc. and reflect CareFusion's results as if the spinoff and certain related transactions had occurred as of the beginning of the fiscal year. These financial results do not necessarily reflect what CareFusion's financial results would have been if it had operated as an independent, publicly traded company during this fiscal period. In addition, these financial results are not necessarily indicative of CareFusion's future results. The assumptions and estimates used and pro forma adjustments derived from such assumptions are based on currently available information, and CareFusion management believes such assumptions are reasonable under the circumstances. For more information, see the CareFusion unaudited pro forma condensed combined financial statements included as an Exhibit 99.5 to Cardinal Health's Form 8-K filed on Aug. 18, 2009.

A reconciliation of the differences between these non-GAAP financial measures and their most directly comparable GAAP financial measures is provided in the attached tables and at cardinalhealth.com. Reconciliations of non-GAAP adjusted Cardinal Health financial measures and pro forma adjusted CareFusion financial measures are also provided in Exhibits 99.4 and 99.5 respectively to Cardinal Health's Form 8-K filed on Aug. 18, 2009.

Cardinal Health uses its Web site as a channel of distribution for material company information. Important information, including news releases, analyst presentations and financial information regarding Cardinal Health is routinely posted and accessible on the investor page at cardinalhealth.com.

This news release contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. These risks and uncertainties include (but are not limited to) uncertainties related to the deferral in hospital capital spending affecting Cardinal Health's Clinical and Medical Products businesses and difficulties in forecasting the exact duration and potential long-term changes in hospital spending patterns; uncertainties and risks regarding the spinoff, including the costs associated with the spinoff and the impact of the spinoff on Cardinal Health, CareFusion and the potential market for their respective securities; competitive pressures in Cardinal Health's various lines of business; the loss of one or more key customer or supplier relationships or changes to the terms of those relationships; uncertainties relating to timing of generic and branded pharmaceutical introductions and the frequency or rate of branded pharmaceutical price appreciation or generic pharmaceutical price deflation; changes in the distribution patterns or reimbursement rates for health care products and/or services; the results, consequences, effects or timing of any inquiry or investigation by any regulatory authority or any legal or administrative proceedings; future actions of regulatory bodies or government authorities relating to Cardinal Health's manufacturing or sale of products and other costs or claims that could arise from its manufacturing, compounding or repackaging operations or from its other services; the effects, timing or success of restructuring programs or plans; the costs, difficulties and uncertainties related to the integration of acquired businesses; uncertainties related to disruptions in the financial markets, including uncertainties related to the availability and/or cost of credit and the impact of financial market disruptions on Cardinal Health's customers and vendors; uncertainties regarding the ultimate features of government health care reform initiatives and their enactment and implementation; and conditions in the pharmaceutical market and general economic and market conditions. In addition, Cardinal Health, CareFusion and the spinoff are subject to additional risks and uncertainties described in Cardinal Health's Form 10-K, Form 10-Q and Form 8-K reports and CareFusion's Form 10 registration statement (including all amendments to those reports and registration statement) and exhibits to those reports and registration statement. This news release reflects management's views as of Aug. 18, 2009. Except to the extent required by applicable law, neither Cardinal Health nor CareFusion undertakes an obligation to update or revise any forward-looking statement.

           CARDINAL HEALTH, INC. AND SUBSIDIARIES
       CONSOLIDATED STATEMENTS OF EARNINGS (UNAUDITED)


                             Fourth Quarter
                             --------------
    (in millions,
     except per Common
     Share amounts)        2009       2008      % Change
                           ----       ----

    Revenue             $25,198.9  $22,894.3        10%
    Cost of products
     sold                23,827.7   21,439.6        11%
                         --------   --------
    Gross margin          1,371.2    1,454.7        (6)%

    Selling, general
     and administrative
     expenses               870.1      895.0        (3)%
    Impairments,
     (gain)/loss on
     sale of assets and
     other, net              11.5      (10.0)      N.M.

    Special items:
      Restructuring
       charges               53.0       10.9       N.M.
      Acquisition
       integration
       charges                2.8       25.1       N.M.
      Litigation and
       other                 (2.0)       6.4       N.M.
                             ----        ---
    Operating earnings      435.8      527.3       (17)%

    Interest expense
     and other               34.6       47.0       (26)%
                             ----       ----
    Earnings before
     income taxes and
     discontinued
     operations             401.2      480.3       (16)%

    Provision for
     income taxes           133.7      164.4       (19)%
                            -----      -----
    Earnings from
     continuing
     operations             267.5      315.9       (15)%

    Earnings from
     discontinued
     operations (net of
     tax expense of
     $2.5 and $5.1 for
     the fourth quarter
     of fiscal 2009 and
     2008, respectively)      5.7        2.1       N.M.
                              ---        ---

    Net earnings           $273.2     $318.0       (14)%
                           ======     ======


    Basic earnings per
     Common Share:
    Continuing
     operations             $0.75      $0.89       (16)%
    Discontinued
     operations              0.01          -       N.M.
                             ----       ----
      Net basic
       earnings per
       Common Share         $0.76      $0.89       (15)%
                            =====      =====

    Diluted earnings
     per Common Share:
    Continuing
     operations             $0.74      $0.88       (16)%
    Discontinued
     operations              0.01          -       N.M.
                             ----       ----
      Net diluted
       earnings per
       Common Share         $0.75      $0.88       (15)%
                            =====      =====

    Weighted average
     number of Common
     Shares outstanding:
    Basic                   358.2      355.5
    Diluted                 361.1      359.8



           CARDINAL HEALTH, INC. AND SUBSIDIARIES
       CONSOLIDATED STATEMENTS OF EARNINGS (UNAUDITED)



                               Fiscal Year
    (in millions,              -----------
     except per Common
     Share amounts)          2009       2008     % Change
                             ----       ----

    Revenue             $99,512.4  $90,975.5         9%
    Cost of products
     sold                93,986.0   85,395.8        10%
                         --------   --------
    Gross margin          5,526.4    5,579.7        (1)%

    Selling, general
     and administrative
     expenses             3,438.3    3,390.1         1%
    Impairments,
     (gain)/loss on
     sale of assets and
     other, net              25.0      (32.0)      N.M.

    Special items:
      Restructuring
       charges              164.3       65.7       N.M.
      Acquisition
       integration
       charges               14.5       44.9       N.M.
      Litigation and
       other                 (1.4)      19.5       N.M.
                             ----       ----
    Operating earnings    1,885.7    2,091.5       (10)%

    Interest expense
     and other              218.7      169.4        29%
                            -----      -----
    Earnings before
     income taxes and
     discontinued
     operations           1,667.0    1,922.1       (13)%

    Provision for
     income taxes           524.2      626.1       (16)%
                            -----      -----
    Earnings from
     continuing
     operations           1,142.8    1,296.0       (12)%

    Earnings from
     discontinued
     operations (net of
     tax expense of $8.6
     and $39.7 for fiscal
     2009 and 2008,
     respectively)            8.8        4.6       N.M.
                              ---        ---

    Net earnings         $1,151.6   $1,300.6       (11)%
                         ========   ========


    Basic earnings per
     Common Share:
    Continuing
     operations             $3.20      $3.62       (12)%
    Discontinued
     operations              0.02       0.01       N.M.
                             ----       ----
      Net basic
       earnings per
       Common Share         $3.22      $3.63       (11)%
                            =====      =====

    Diluted earnings
     per Common Share:
    Continuing
     operations             $3.16      $3.56       (11)%
    Discontinued
     operations              0.02       0.01       N.M.
                             ----       ----
      Net diluted
       earnings per
       Common Share         $3.18      $3.57       (11)%
                            =====      =====

    Weighted average
     number of Common
     Shares outstanding:
    Basic                   357.6      358.2
    Diluted                 361.5      364.0



                 CARDINAL HEALTH, INC. AND SUBSIDIARIES
                 CONSOLIDATED BALANCE SHEETS (UNAUDITED)

                                                   June 30,  June 30,
    (in millions)                                   2009       2008
                                                    ----       ----

    Assets
    Cash and equivalents                           $1,847.5  $1,291.3
    Trade receivables, net                          5,643.6   4,987.7
    Current portion of net investment in sales-
     type leases                                      398.9     383.7
    Inventories                                     7,145.5   6,757.7
    Prepaid expenses and other                        588.8     591.4
    Assets from businesses held for sale and
     discontinued operations                          174.7     264.2
                                                      -----     -----
      Total current assets                         15,799.0  14,276.0
                                                   --------  --------

    Property and equipment, net                     1,873.0   1,714.0
    Net investment in sales-type leases, less
     current portion                                  929.8     916.8
    Goodwill and other intangibles, net             6,095.9   6,157.3
    Other assets                                      421.1     384.1
                                                      -----     -----
      Total assets                                $25,118.8 $23,448.2
                                                  ========= =========


    Liabilities and Shareholders' Equity
    Current portion of long-term obligations and
     other short-term borrowings                     $367.3    $159.0
    Accounts payable                                9,138.0   8,303.8
    Other accrued liabilities                       1,868.2   1,874.9
    Liabilities from businesses held for sale
     and discontinued operations                       26.3      50.0
                                                       ----      ----
      Total current liabilities                    11,399.8  10,387.7
                                                   --------  --------

    Long-term obligations, less current portion
     and other short-term borrowings                3,280.0   3,687.4
    Deferred income taxes and other liabilities     1,714.3   1,625.6
      Total shareholders' equity                    8,724.7   7,747.5
                                                    -------   -------
      Total liabilities and shareholders' equity  $25,118.8 $23,448.2
                                                  ========= =========



                 CARDINAL HEALTH, INC. AND SUBSIDIARIES
            CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

                               Fourth Quarter        Fiscal Year
                               --------------        -----------
      (in millions)            2009      2008      2009      2008
                               ----      ----      ----      ----

      Cash Flows From
       Operating Activities:
      Net earnings           $273.2    $318.0  $1,151.6  $1,300.6
      Earnings from
       discontinued
       operations              (5.7)     (2.1)     (8.8)     (4.6)
                               ----      ----      ----      ----
        Earnings from
         continuing
         operations           267.5     315.9   1,142.8   1,296.0
      Adjustments to
       reconcile earnings
       from continuing
       operations to net
       cash provided by /
       (used in) operating
       activities:
        Depreciation and
         amortization         110.6      94.9     399.4     374.8
        Asset impairments
         and (gain)/loss
         on sale of
         assets, net           11.5      (9.4)     25.0     (31.4)
        Purchased in-
         process research
         and development          -      18.0         -      18.0
        Equity
         compensation          30.5      35.6     122.8     122.3
        Provision for
         deferred income
         taxes                 69.5      25.8      69.5      25.8
        Provision for bad
         debts                  5.8       3.8      59.4      26.1
      Change in operating
       assets and liabilities,
       net of effects from
       acquisitions:
        (Increase)/
         decrease in trade
         receivables          232.7     (18.9)   (646.1)   (313.1)
        (Increase)/
         decrease in
         inventories          912.6     499.2    (341.8)    614.3
        (Increase)/
         decrease in net
         investment in
         sales-type leases      8.0     (41.1)    (28.2)   (124.9)
        Increase/
         (decrease) in
         accounts payable    (889.6)   (638.4)    749.0    (859.9)
        Other accrued
         liabilities and
         operating items,
         net                   84.4     (48.0)      6.5     405.6
                               ----     -----       ---     -----
          Net cash
           provided by
           operating
           activities -
           continuing
           operations         843.5     237.4   1,558.3   1,553.6
          Net cash
           provided by/
           (used in)
           operating
           activities -
           discontinued
           operations         (16.8)      4.9       9.0     (36.0)
                              -----       ---       ---     -----
      Net cash provided
       by operating
       activities             826.7     242.3   1,567.3   1,517.6
                              -----     -----   -------   -------

      Cash Flows From
       Investing Activities:
      Acquisition of
       subsidiaries, net
       of divestitures and
       cash acquired              -    (475.9)     (5.3)   (514.9)
      Proceeds from sale
       of property and
       equipment                1.0      22.4      13.5      32.6
      Additions to
       property and
       equipment             (271.4)   (120.8)   (533.4)   (366.0)
      Sale of investment
       securities
       available for sale,
       net                        -         -         -     132.0
                               ----     -----       ---     -----
          Net cash used
           in investing
           activities -
           continuing
           operations        (270.4)   (574.3)   (525.2)   (716.3)
          Net cash used
           in investing
           activities -
           discontinued
           operations          (3.4)     (3.7)    (17.7)    (10.1)
                               ----      ----     -----     -----
      Net cash used in
       investing
       activities            (273.8)   (578.0)   (542.9)   (726.4)
                             ------    ------    ------    ------

      Cash Flows From
       Financing Activities:
      Net change in
       commercial paper
       and short-term
       borrowings                (-)   (202.7)        -      (0.5)
      Reduction of long-
       term obligations         5.5      (4.6)   (304.6)    (21.5)
      Proceeds from long-
       term obligations,
       net of issuance
       costs                  (24.4)    302.5       0.4     303.5
      Proceeds from
       issuance of Common
       Shares                   0.5      18.6      39.3     227.9
      Tax benefit/
       (expense) from
       stock options           (2.7)     26.8      (2.9)     42.1
      Dividends on Common
       Shares                 (50.3)    (42.6)   (200.4)   (173.1)
      Purchase of Common
       Shares in treasury         -         -         -  (1,181.6)
                               ----     -----      ----     -----
          Net cash
           provided by/
           (used in)
           financing
           activities -
           continuing
           operations         (71.4)     98.0    (468.2)   (803.2)
          Net cash
           provided by/
           (used in)
           financing
           activities -
           discontinued
           operations             -         -         -         -
                               ----     -----      ----     -----
      Net cash provided
       by/(used in)
       financing
       activities             (71.4)     98.0    (468.2)   (803.2)
                              -----      ----    ------    ------

      Net increase/
       (decrease) in cash
       and equivalents        481.5    (237.7)    556.2     (12.0)

      Cash and
       equivalents at
       beginning of period  1,366.0   1,529.0   1,291.3   1,303.3
                            -------   -------   -------   -------

      Cash and
       equivalents at end
       of period           $1,847.5  $1,291.3  $1,847.5  $1,291.3
                           ========  ========  ========  ========



                       CARDINAL HEALTH, INC. AND SUBSIDIARIES
                                  BUSINESS ANALYSIS

                                    TOTAL COMPANY

                                                                 Non-GAAP
                                            Fourth Quarter    Fourth Quarter
                                            --------------    --------------
      (in millions)                         2009      2008    2009     2008
                                            ----      ----    ----     ----

      Revenue
      Amount                               $25,199   $22,894
      Growth Rate                               10%        3%

      Operating Earnings
      Amount                                  $436      $527    $509     $560
      Growth Rate                              (17)%      27%     (9)%      5%

      Earnings from Continuing Operations
      Amount                                  $268      $316    $311     $342
      Growth Rate                              (15)%      36%     (9)%      1%


                                                                  Non-GAAP
                                             Fiscal Year        Fiscal Year
                                             -----------        -----------
                                             2009      2008     2009     2008
                                             ----      ----     ----     ----

      Revenue
      Amount                               $99,512   $90,976
      Growth Rate                                9%        5%

      Operating Earnings
      Amount                                $1,886    $2,092  $2,098   $2,190
      Growth Rate                              (10)%      55%     (4)%      3%

      Earnings from Continuing Operations
      Amount                                $1,143    $1,296  $1,256   $1,365
      Growth Rate                              (12)%      58%     (8)%      -

    Refer to the GAAP / Non-GAAP Reconciliation for definitions and
    calculations supporting the non-GAAP balances.



                   CARDINAL HEALTH, INC. AND SUBSIDIARIES
                         SEGMENT BUSINESS ANALYSIS


                       Fourth Quarter                   Fourth Quarter
                       --------------                   --------------
    (in millions)      2009      2008   (in millions)    2009     2008
                       ----      ----                    ----     ----

    HEALTHCARE                          CLINICAL AND
     SUPPLY CHAIN                        MEDICAL
     SERVICES                            PRODUCTS

    Revenue (1)                         Revenue (1)
    Amount          $24,318   $21,832   Amount         $1,119   $1,270
    Growth Rate          11%        2%  Growth Rate       (12)%     25%
    Mix                  95%       93%  Mix                 4%       6%

    Segment Profit(2)                   Segment Profit(2)
    Amount             $341      $316   Amount           $157     $229
    Growth Rate           8%      (13)% Growth Rate       (32)%     20%
    Mix                  66%       55%  Mix                31%      40%
    Segment Profit                      Segment Profit
     Margin            1.40%     1.45%   Margin         13.99%   18.04%



                       Fourth Quarter
                       --------------
    (in millions)      2009      2008
                       ----      ----

    ALL OTHER

    Revenue (1)
    Amount             $234      $288
    Growth Rate         (19)%       1%
    Mix                   1%        1%

    Segment Profit (2)
    Amount              $17       $27
    Growth Rate         (36)%       9%
    Mix                   3%        5%
    Segment Profit
     Margin            7.44%     9.41%


    Refer to definitions for an explanation of calculations.

    (1) Total consolidated revenue for the three months ended June 30, 2009
        was $25.2 billion, which included total segment revenue of $25.7
        billion and Corporate revenue of $(0.5) billion.  Total consolidated
        revenue for the three months ended June 30, 2008 was $22.9 billion,
        which included total segment revenue of $23.4 billion and Corporate
        revenue of $(0.5) billion.  Corporate consists primarily of
        elimination of inter-segment revenue.

    (2) Total consolidated operating earnings for the three months ended June
        30, 2009 were $436 million, which included total segment profit of
        $515 million and Corporate loss of $(79) million.  Total consolidated
        operating earnings for the three months ended June 30, 2008 were $527
        million, which included total segment profit of $572 million and
        Corporate loss of $(45) million.  Corporate includes, among other
        things, special items and impairments, (gain)/loss on sale of assets
        and other, net.



                     CARDINAL HEALTH, INC. AND SUBSIDIARIES
                            SEGMENT BUSINESS ANALYSIS


                            Fiscal Year                      Fiscal Year
                            -----------                      -----------
      (in millions)        2009     2008   (in millions)    2009     2008
                           ----     ----                    ----     ----

      HEALTHCARE                           CLINICAL AND
       SUPPLY CHAIN                         MEDICAL
       SERVICES                             PRODUCTS

      Revenue (1)                          Revenue (1)
      Amount            $95,718  $87,110   Amount         $4,588   $4,606
      Growth Rate            10%       4%  Growth Rate        (-)%     30%
      Mix                    94%      94%  Mix                 5%       5%

      Segment Profit(2)                    Segment Profit(2)
      Amount             $1,339   $1,333   Amount           $670     $735
      Growth Rate             -%     (12)% Growth Rate        (9)%     37%
      Mix                    64%      61%  Mix                32%      34%
      Segment Profit                       Segment
       Margin              1.40%    1.53%   Profit Margin  14.59%   15.96%



                               Fiscal Year
                               -----------
      (in millions)            2009     2008
                               ----     ----

      ALL OTHER

      Revenue (1)
      Amount                 $1,018   $1,190
      Growth Rate               (14)%      3%
      Mix                         1%       1%

      Segment Profit (2)
      Amount                    $95     $101
      Growth Rate                (5)%     (6)%
      Mix                         4%       5%
      Segment Profit Margin    9.36%    8.45%


    Refer to definitions for an explanation of calculations.

    (1) Total consolidated revenue for the fiscal year ended June 30, 2009 was
        $99.5 billion, which included total segment revenue of $101.3 billion
        and Corporate revenue of $(1.8) billion.  Total consolidated revenue
        for the fiscal year ended June 30, 2008 was $91.0 billion,
        which included total segment revenue of $92.9 billion and Corporate
        revenue of $(1.9) billion.  Corporate consists primarily of
        elimination of inter-segment revenue.

    (2) Total consolidated operating earnings for the fiscal year ended June
        30, 2009 were $1,886 million, which included total segment profit of
        $2,104 million and Corporate loss of $(218) million.  Total
        consolidated operating earnings for the fiscal year ended June 30,
        2008 were $2,092 million, which included total segment profit of
        $2,169 million and Corporate loss of $(77) million.  Corporate
        includes, among other things, special items and impairments, (gain)/
        loss on sale of assets and other, net.



                   CARDINAL HEALTH, INC. AND SUBSIDIARIES
                         SCHEDULE OF NOTABLE ITEMS



                                        Fourth Quarter    Fiscal Year
                                        --------------    -----------
      (in millions, except per Common
       Share amounts)                    2009    2008     2009    2008
                                         ----    ----     ----    ----


      Special Items
      Restructuring charges            $(53.0) $(10.9) $(164.3) $(65.7)
      Acquisition integration charges    (2.8)  (25.1)   (14.5)  (44.9)
      Litigation and other                2.0    (6.4)     1.4   (19.5)
                                          ---    ----      ---   -----
        Total special items             (53.8)  (42.4)  (177.4) (130.1)
        Tax benefit                      15.2    12.0     51.6    43.8
                                         ----    ----     ----    ----
        Special items, net of tax      $(38.6) $(30.4) $(125.8) $(86.3)
                                       ======  ======  =======  ======

        Decrease to diluted EPS from
         continuing operations         $(0.11) $(0.09)  $(0.35) $(0.24)
                                       ======  ======   ======  ======



      Other Spin-Off Costs
      Other spin-off costs              $(8.4)     $-   $(10.4)     $-
        Tax benefit                       3.1       -      3.9       -
                                          ---     ---      ---     ---
        Other spin-off costs,
         net of tax                     $(5.3)     $-    $(6.5)     $-
                                        =====     ===    =====     ===

        Decrease to diluted EPS
         from continuing operations    $(0.01)     $-   $(0.02)     $-
                                       ======     ===   ======     ===


      Impairments, Gain/(Loss)
       on Sale of Assets and
       Other, Net
      Impairments, gain/(loss) on
       sale of assets and other,
       net (1)                         $(11.5)  $10.0   $(25.0)  $32.0
        Tax benefit / (expense)          11.8    (6.0)    43.5   (14.4)
                                         ----    ----     ----   -----
        Impairments, gain/(loss)
         on sale of assets and
         other, net, net of tax          $0.3    $4.0    $18.5   $17.6
                                         ====    ====    =====   =====

        Increase to diluted EPS
         from continuing operations        $-   $0.01    $0.05   $0.05
                                          ===   =====    =====   =====



      Weighted Average Number
       of Diluted Shares
       Outstanding                      361.1   359.8    361.5   364.0


    (1)Other spin-off costs included in selling, general and administrative
       expenses and interest expense and other for the three months ended June
       30, 2009 were $8.1 million and $0.3 million, respectively.  Other spin-
       off costs included in selling, general and administrative expenses and
       interest expense and other for the fiscal year ended  June 30, 2009
       were $10.1 million and $0.3 million, respectively.



                 CARDINAL HEALTH, INC. AND SUBSIDIARIES
                        ASSET MANAGEMENT ANALYSIS


                                             Fourth      Fiscal
                                             Quarter      Year
                                            --------   -----------
                                           2009  2008  2009  2008
                                           ----  ----  ----  ----


      Receivable Days                      20.1  20.9
      Days Inventory on Hand                 24    25


      Debt to Total Capital                  29%   33%
      Net Debt to Capital                    17%   25%


      Return on Equity                     12.7% 16.8% 14.1% 17.7%
      Non-GAAP Return on Equity            14.8% 18.2% 15.4% 18.8%


      Return on Invested Capital           5.97% 7.35% 6.63% 7.55%
      Non-GAAP Return on Invested Capital  6.85% 7.91% 7.21% 7.96%


      Effective Tax Rate from
       Continuing Operations               33.3% 34.2% 31.4% 32.6%
      Non-GAAP Effective Tax
       Rate from Continuing Operations     34.5% 33.2% 33.2% 32.4%

    Refer to the GAAP / Non-GAAP Reconciliation for non-GAAP calculations.



                     CARDINAL HEALTH, INC. AND SUBSIDIARIES
                         GAAP / NON-GAAP RECONCILIATION



                                           Fourth Quarter 2009
                            -------------------------------------------------
                                                        Impairments,
                                                        (Gain)/Loss
    (in millions,                             Other     on Sale of
     except per Common              Special  Spin-Off   Assets and
     Share amounts)         GAAP    Items     Costs     Other, Net   Non-GAAP


    Operating Earnings
    Amount                 $436        $54        $8           $12     $509
    Growth Rate             (17)%                                        (9)%

    Provision for
     Income Taxes          $134        $15        $3           $12     $164

    Earnings from
     Continuing Operations
    Amount                 $268        $39        $5            $-     $311
    Growth Rate             (15)%                                        (9)%

    Diluted EPS from
     Continuing Operations
    Amount                $0.74      $0.11     $0.01            $-    $0.86
    Growth Rate             (16)%                                       (10)%



                                            Fiscal Year 2009
                           ---------------------------------------------------
                                                        Impairments,
                                                        (Gain)/Loss
    (in millions,                             Other     on Sale of
     except per Common              Special  Spin-Off   Assets and
     Share amounts)        GAAP     Items     Costs     Other, Net    Non-GAAP


    Operating Earnings
    Amount               $1,886       $177       $10           $25    $2,098
    Growth Rate             (10)%                                         (4)%

    Provision for
     Income Taxes          $524        $52        $4           $44      $623

    Earnings from
     Continuing Operations
    Amount               $1,143       $126        $7          ($19)   $1,256
    Growth Rate             (12)%                                        (8)%

    Diluted EPS from
     Continuing Operations
    Amount                $3.16      $0.35     $0.02        ($0.05)    $3.48
    Growth Rate             (11)%                                         (7)%



                                          Fourth Quarter 2008
                            -------------------------------------------------
                                                       Impairments,
                                                       (Gain)/Loss
                                             Other     on Sale of
                                   Special  Spin-Off   Assets and
                            GAAP   Items     Costs     Other, Net    Non-GAAP


    Operating Earnings
    Amount                 $527       $42        $-          ($10)     $560
    Growth Rate              27%                                          5%

    Provision for
     Income Taxes          $164       $12        $-           ($6)     $170

    Earnings from
     Continuing Operations
    Amount                 $316       $30        $-           ($4)     $342
    Growth Rate              36%                                          1%

    Diluted EPS from
     Continuing Operations
    Amount                $0.88     $0.09        $-        ($0.01)    $0.96
    Growth Rate              47%                                          9%



                                            Fiscal Year 2008
                            --------------------------------------------------
                                                        Impairments,
                                                        (Gain)/Loss
                                              Other     on Sale of
                                    Special  Spin-Off   Assets and
                            GAAP    Items     Costs     Other, Net    Non-GAAP


    Operating Earnings
    Amount                $2,092      $130        $-          ($32)   $2,190
    Growth Rate               55%                                          3%

    Provision for
     Income Taxes           $626       $44        $-          ($14)     $655

    Earnings from
     Continuing Operations
    Amount                $1,296       $86        $-          ($18)   $1,365
    Growth Rate               58%                                          -%

    Diluted EPS from
     Continuing Operations
    Amount                 $3.56     $0.24        $-        ($0.05)    $3.75
    Growth Rate               75%                                         11%


    The sum of the components may not equal the total due to rounding.



                   CARDINAL HEALTH, INC. AND SUBSIDIARIES
                       GAAP / NON-GAAP RECONCILIATION


                                Fourth Quarter          Fiscal Year
                                --------------          -----------
      (in millions)             2009       2008       2009       2008
                                ----       ----       ----       ----


      GAAP Return on
       Equity                   12.7%      16.8%      14.1%      17.7%

      Non-GAAP Return on
       Equity
      Net earnings            $273.2     $318.0   $1,151.6   $1,300.6
      Special items, net
       of tax, in
       continuing
       operations               38.6       30.4      125.8       86.3
      Other spin-off
       costs, net of tax         5.3          -        6.5          -
      Impairments, (gain)/
       loss on sale of
       assets and other,
       net, net of tax, in
       continuing
       operations               (0.3)      (4.0)     (18.5)     (17.6)
      Gain on sale of
       PTS, net of tax, in
       discontinued
       operations                  -          -          -        7.6
                                ----       ----       ----       ----
        Adjusted net
         earnings             $316.8     $344.4   $1,265.4   $1,376.9

        Annualized          $1,267.2   $1,377.6   $1,265.4   $1,376.9

        Divided by average
         shareholders'
         equity (1)         $8,579.6   $7,570.4   $8,190.5   $7,338.8


      Non-GAAP return on
       equity                   14.8%      18.2%      15.4%      18.8%


                                Fourth Quarter          Fiscal Year
                                --------------          -----------
                                2009       2008       2009       2008
                                ----       ----       ----       ----


      GAAP Return on
       Invested Capital         5.97%      7.35%      6.63%      7.55%

      Non-GAAP Return on
       Invested Capital
      Net earnings            $273.2     $318.0   $1,151.6   $1,300.6
      Special items, net
       of tax, in
       continuing
       operations               38.6       30.4      125.8       86.3
      Other spin-off
       costs, net of tax         5.3          -        6.5          -
      Impairments, (gain)/
       loss on sale of
       assets and other,
       net, net of tax, in
       continuing
       operations               (0.3)      (4.0)     (18.5)     (17.6)
      Interest expense
       and other, net of
       tax                      21.9       30.0      139.3      108.4
      Gain on sale of
       PTS, net of tax, in
       discontinued
       operations                  -          -          -        7.6
                                ----       ----       ----       ----
        Adjusted net
         earnings             $338.7     $374.4   $1,404.7   $1,485.3

        Annualized          $1,354.8   $1,497.6   $1,404.7   $1,485.3

        Divided by average
         total invested
         capital (2)       $19,778.3  $18,935.7  $19,487.0  $18,664.2


      Non-GAAP return on
       invested capital         6.85%      7.91%      7.21%      7.96%



    (1)The average shareholders' equity shown above is calculated
       using the average of the prior and current quarters except for
       year-to-date which is calculated as the average of
       shareholders' equity at the end of the prior years' fourth
       quarter plus each of the current year quarters.


    (2)Total invested capital is calculated as the sum of the current
       portion of long-term obligations and other short-term
       borrowings, long-term obligations, total shareholders' equity
       and unrecorded goodwill. The average total invested capital is
       calculated using the average of total invested capital at the
       end of the prior and current quarters except for year-to-date
       whi
'/>"/>
SOURCE Cardinal Health, Inc.
Copyright©2009 PR Newswire.
All rights reserved


Related medicine news :

1. George Barrett Named Chairman and CEO of Cardinal Health
2. NFL Cardinals Wide Receiver Larry Fitzgerald Promotes Vision Therapy
3. Cardinal Health Welcomes Record Number of Attendees at its Annual Independent Pharmacy Trade Show
4. Cardinal Health Announced as Title Sponsor of the Health Connect Partners 2009 Fall Hospital Pharmacy Conference
5. Cardinal Health Names Patricia Morrison Chief Information Officer
6. Cardinal Health Board of Directors Approves CareFusion Spinoff
7. Cardinal Rigali Criticizes Final NIH Guidelines for Destructive Stem Cell Research
8. Cardinal Health Renews Distribution Agreement With CVS Caremark
9. Cardinal Health Appoints Bruce Downey to Board of Directors; John McCoy Retires From Board After 22 Years
10. Boston Cardinal OMalley Withdraws Caritas Christi From Potential Abortion Scandal
11. Cardinal Health Foundation Awards $1 Million to Fund Patient Safety Initiatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... ... Dr. Justin Scott and Dr. Lydia Muccioli of Pure Dental Health ... need. The event is scheduled to take place on February 27, 2016 from 9am ... care to community members in need. Each patient will be given the opportunity to ...
(Date:2/5/2016)... San Francisco, CA (PRWEB) , ... February 05, ... ... dentist and founder of CitiDent, announces that it is now welcoming ... by Dr. Cheng, CitiDent offers a complete range of oral health care, including ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... In sleep, ... form as a dream. A hallmark feature of patients with eating disorders is significant ... The eating disorder behaviors and obsessions are regarded as maladaptive means for coping with ...
(Date:2/5/2016)... ... ... California Mobile Kitchens , a company that designs ... kitchen model, featuring customizable stainless steel interiors and a new, 26-foot unit. , ... in the U.S. Many of their units can be seen at sporting events, ...
(Date:2/5/2016)... ... ... Calls Blacklist has just been updated by mobile app developer Vlad Lee. ... fixed known bugs within the app. Calls Blacklist allows its users to only have ... of their device’s battery power or memory. It provides a powerful call blocker that ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... 5, 2016  Aralez Pharmaceuticals Inc. ("Aralez") today announced ... ("POZEN") and Tribute Pharmaceuticals Canada Inc. ("Tribute") following approval of ... Tribute. The combined company will operate under Aralez Pharmaceuticals ... in Canada , Ireland ... . Under the terms of the Agreement and Plan ...
(Date:2/5/2016)... , Feb. 5, 2016 Dehaier Medical ... or the "Company"), which develops, markets and sells ... China and international markets, ... which aims to concentrate the Company,s resources to ... respiratory business and to focus more on its ...
(Date:2/5/2016)... February 4, 2016 France , ... , UK, and Israel ). It includes a ... and 3 GD, segmented by age and sex in these markets. GD ... EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis ... , Germany , Italy , ...
Breaking Medicine Technology: